Skip to Content
Merck
All Photos(1)

Documents

A0722

Sigma-Aldrich

Apolipoprotein A-I from human plasma

≥85% (SDS-PAGE), buffered aqueous solution

Synonym(s):

Apo A-I

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

MDL number:
MFCD00132610
UNSPSC Code:
12352202
NACRES:
NA.32

biological source

human plasma

Quality Level

300

Assay

≥85% (SDS-PAGE)

form

buffered aqueous solution

mol wt

28.3 kDa

technique(s)

ELISA: suitable

UniProt accession no.

P02647

shipped in

dry ice

storage temp.

−20°C

Gene Information

human ... APOA1(335)

Looking for similar products? Visit Product Comparison Guide

Application

Apolipoprotein A-I from human plasma has been used to induce cholesterol efflux in nitrobenzoxadiazole (NBD)-cholesterol loaded cells. It has also been used to detect IgG anti-apoA-1 antibodies using enzyme linked immunosorbent assay (ELISA).
Major protein components in high density lipoprotein (HDL)

Biochem/physiol Actions

Apo-AI comprises ~70% of the protein moiety in HDL. It is a single polypeptide chain consisting of 245 amino acids with glutamic acid as the C-terminal residue and aspartic acid as the N-terminal residue. The molecular mass is reported to be 28.3 kDa. The protein is made up of one major isoform (pI 5.6) and two minor isoforms (pI 5.53 and 5.46). Apo-AI shows a high content of α-helix structure. The amphipathic regions in the α-helix structure seem to be responsible for lipid binding capacity. In aqueous solution, Apo-AI shows self-association with minor conformation change. Apo-AI activates lecithin-cholesterol (LCAT) acyltransferase, which is responsible for cholesterol esterification in plasma.

Apo-AI levels in normal plasma are 90-130 mg/dl. Apo-AI levels may be inversely related to the risk of coronary disease.

Physical form

Solution in 10 mM ammonium bicarbonate

Disclaimer

RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.

Storage Class Code

10 - Combustible liquids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Sara Croca et al.
Arthritis research & therapy, 17, 26-26 (2015-04-19)
IgG anti-apolipoprotein A-1 (IgG anti-apoA-1) antibodies are present in patients with systemic lupus erythematosus (SLE) and may link inflammatory disease activity and the increased risk of developing atherosclerosis and cardiovascular disease (CVD) in these patients. We carried out a rigorous
H J Menzel et al.
The Journal of biological chemistry, 259(5), 3070-3076 (1984-03-10)
Variant forms of apolipoprotein A-I (apo-A-I) have been shown to exist in the human population. One mutant form, referred to as apo-A-I-Münster-3, is one charge unit more basic than normal apo-A-I on isoelectric focusing gels. This variant has the same
Gantsetseg Tumurkhuu et al.
Cell metabolism, 28(3), 432-448 (2018-06-26)
Pathogen burden accelerates atherosclerosis, but the mechanisms remain unresolved. Activation of the NLRP3 inflammasome is linked to atherogenesis. Here we investigated whether Chlamydia pneumoniae (C.pn) infection engages NLRP3 in promoting atherosclerosis. C.pn potentiated hyperlipidemia-induced inflammasome activity in cultured macrophages and
J O Lagerstedt et al.
Journal of internal medicine, 285(1), 49-58 (2018-07-22)
IgG antibodies against apolipoprotein A-I (ApoA-I) have been found to be elevated in subjects from the general population with clinically manifest cardiovascular disease and in myocardial infarction patients with an adverse prognosis. Here, we investigated whether these antibodies are prospectively
Gabriele Romano et al.
International journal of cardiology, 271, 233-239 (2018-06-17)
Atherosclerosis is a slowly progressing, chronic multifactorial disease characterized by the accumulation of lipids, inflammatory cells, and fibrous tissue that drives to the formation of asymmetric focal thickenings in the tunica intima of large and mid-sized arteries. Despite the high
View All Related Papers

Articles

Cholesterol Transport

Lipoproteins package cholesterol for transport in plasma, essential for lipid transport and cellular function in the body.

Cholesterol Transport

Lipoproteins package cholesterol for transport in plasma, essential for lipid transport and cellular function in the body.

Cholesterol Transport

Lipoproteins package cholesterol for transport in plasma, essential for lipid transport and cellular function in the body.

Cholesterol Transport

Lipoproteins package cholesterol for transport in plasma, essential for lipid transport and cellular function in the body.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service